ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Disagree

<< Previous

Bullboard Posts

Next >>

Comment by Speyeder999on Oct 13, 2021 10:56am

149 Views

Post# 34000917

RE:RE:RE:Disagree

Thanks for all the replies.
I only ask because volume seems to have surprisingly dried up over the course of the last month, keeping well in mind that there is 430M shares out there and not sure how a share consolidation to a float of under 20M shares can stir up much interest from analysts and insiders holding a huge chunk.

<< Previous

Bullboard Posts

Next >>

Canadian government to fund Electric Royalties portfolio property